Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06052839 · ClinicalTrials.gov registry record · Phase 2
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
A Phase 2 study of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC), sponsored by Dan Zandberg.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06052839 is a Phase 2 study of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) that is actively recruiting participants, run by Dan Zandberg. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06052839, a Phase 2 study of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC), is actively recruiting participants, sponsored by Dan Zandberg.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The rationale for the new sequence of pulsed dose chemotherapy proposed in this trial is based on the hypotheses that current standard dosing of chemotherapy plus pembrolizumab ultimately suppresses the immune system and has a negative effect on the efficacy of the anti-PD-1 monoclonal antibody (mAb) therapy and that chemotherapy given after anti-PD-1 mAb therapy is associated with higher efficacy.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Paclitaxel
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-10-03 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06052839
The ClinicalTrials.gov registry entry for NCT06052839 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dan Zandberg, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT06052839 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06052839 about?
NCT06052839 is a clinical study titled "Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC". The rationale for the new sequence of pulsed dose chemotherapy proposed in this trial is based on the hypotheses that current standard dosing of chemotherapy plus pembrolizumab ultimately suppresses the immune system and has a negative effect on the efficacy of the anti-PD-1 monoclonal antibody (mAb...
What is the current status of trial NCT06052839?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2023-10-03. Estimated completion is 2027-12-31.
What conditions does trial NCT06052839 study?
This clinical trial studies the following conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC).
What interventions are being tested in trial NCT06052839?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT06052839?
This trial is sponsored by Dan Zandberg, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06052839 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.